People living in India’s capital city of Delhi has higher rates of diabetes and hypertension incidence compared to other metros like Mumbai, according to the findings of a new study conducted by Aventis Pharma Ltd.
21% of Delhiites suffer from both diabetes and hypertension leading to a possible twin epidemic, shows the New Delhi results of the SITE (Screening India’s Twin Epidemic) study.
The New Delhi results follow the Maharashtra results announcement in November 2009. The results of other States covered in the SITE study will be shared over the next few months.
SITE is the first cross-sectional study to assess the prevalence of diagnosed and undiagnosed cases of diabetes and hypertension amongst nearly 20,000 patients visiting general practitioners and consultant physicians across major cities all over India. The SITE study has been commissioned by sanofi-aventis in order to quantify and increase awareness of diabetes and hypertension becoming twin epidemics in India.
Of the diabetic population in New Delhi already aware of their condition, almost two-of-every-three (62%) had ‘uncontrolled’ diabetes with their Hba1c levels more than 7% and of the hypertensive population three-out-of-four were uncontrolled.
Almost half the population tested in the New Delhi region has uncontrolled levels of lipids (dyslipidemia) as compared to about one-fifth of the Maharashtra population.
“The comprehensive data on diabetes and hypertension collected for SITE New Delhi shows that 62% of the diabetic population were inadequately controlled inspite of treatment. What was even more alarming was that 27% of the diabetic patients screened, had kidney complications. In addition, we noticed that 65% of the diabetic patients were also hypertensive and dyslipidemia at 55% was equally high amongst both the diabetic and hypertensive populations,” pointed out Dr. Ambrish Mithal, chairman, head Of department, Division of Endocrinology and Diabetes, Medanta – The Medicity and Senior Consultant – Endocrinology & Diabetes, Department of Endocrinology, Indraprastha Apollo Hospitals, one of the state coordinators of the sanofi-aventis SITE study in New Delhi.
Cardiovascular death rates are high and appear to be climbing in countries like India where diabetes is highly prevalent.
In India, in the past five decades, rates of coronary disease among urban population have risen from 4% to 11%.
The World Health Organisation (WHO) estimates that 60% of the world’s cardiac patients will be Indians by 2010. With the rising tide of diabetes in India, the double jeopardy of diabetes and hypertension is set to result in an explosion of cardiovascular and other complications – unless preventive action is taken now, alerts the Sanofi study.
Screening India’s Twin Epidemics (SITE) study was started in Maharashtra in January 2009. New Delhi is the second center (1980 patients) to conclude the study after the principal coordinators of SITE announced the completion of the study which surveyed 1842 patients in Maharashtra.
SITE is a national, multi-centric, non randomized, observational study with the aim of collecting information on the prevalence of diagnosed and undiagnosed diabetes and hypertension cases in out-patient clinics in major Indian cities and to understand the extent of associated risk factors among these patients.
The study will screen 20,000 patients, covering a wide variety of people aged 18 years and above, including businessmen, working professionals, adult students and housewives. The study across 1,000 centers mainly in the metros in Maharashtra, New Delhi, West Bengal, Tamil Nadu, Andhra Pradesh, Karnataka, Gujarat, Uttar Pradesh, Rajasthan and Madhya Pradesh was commissioned by sanofi-aventis India with the aim of understanding the management and level of control for diabetes and hypertension in the country and then creating awareness amongst doctors and patients regarding the need for early diagnosis for better disease management.
The sanofi-aventis SITE study has taken into account various parameters – medical history, family history, diet, demographic data – height, weight, waist and hip circumference, blood pressure, pulse, treatment history and fasting blood test for lipids, glucose, (including HbA1c) as well as urine for proteins.
Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy.
More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. According to the World Health Organization estimates, India had 32 million diabetic subjects in the year 2000 and this number would increase to 80 million by the year 2030.
The International Diabetes Federation has reported that the 50.8 million diabetic subjects in India in 2010 would rise to 87 million by the year 2030. It is quite evident from the above observations that diabetes has become a major health problem in India.
Sanofi-aventis in India operates through four entities – Aventis Pharma Limited, Sanofi-Synthelabo (India) Limited, Sanofi Pasteur India Private Limited and Shantha Biotechnics. Sanofi-aventis and its 100% subsidiary Hoechst GmbH are the major shareholders of Aventis Pharma Limited and together hold 50.12% of its paid-up share capital.
Sanofi-Synthelabo (India) Limited and Sanofi Pasteur are 100% subsidiaries of sanofi-aventis Group. Aventis Pharma Limited is listed on the Bombay Stock Exchange and the National Stock Exchange. The Company focuses its activities on seven major therapeutic areas namely – cardiovascular diseases, metabolic disorders, thrombosis, oncology, central nervous system disorders, internal medicine and vaccines.